

**(12) PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 200069850 B2**  
**(10) Patent No. 781994**

(54) Title  
**Composition for IVF**

(51)<sup>7</sup> International Patent Classification(s)  
**A61K 031/00**

(21) Application No: **200069850**

(22) Application Date: **2000.09.11**

(87) WIPO No: **WO01/19354**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>PA 1999 01308</b>	<b>1999.09.16</b>	<b>DK</b>

(43) Publication Date : **2001.04.17**

(43) Publication Journal Date : **2001.06.14**

(44) Accepted Journal Date : **2005.06.23**

(71) Applicant(s)  
**Novo Nordisk A/S**

(72) Inventor(s)  
**Tina Meinertz Andersen**

(74) Agent/Attorney  
**Shelston IP,Level 21,60 Margaret Street,SYDNEY NSW 2000**

(56) Related Art  
**WO 1998/028323**  
**WO 1998/024883**  
**WO 1990/003429**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
WO 01/19354 A3

- (51) International Patent Classification<sup>7</sup>: A61K 47/42 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/DK00/00500
- (22) International Filing Date: 11 September 2000 (11.09.2000) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: PA 1999 01308 16 September 1999 (16.09.1999) DK  
Published:  
— With international search report.  
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).
- (72) Inventor: ANDERSEN, Tina, Meinertz; Slettevang 3, DK-2970 Hørsholm (DK). (88) Date of publication of the international search report: 14 June 2001
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/19354 A3

(54) Title: COMPOSITION FOR IVF

(57) Abstract: A solid composition containing a meiosis activating substance can be prepared by adding a protein or a phosphoglycid.

## COMPOSITION FOR IVF

The present invention relates to a solid product which can be used in connection with *in vitro* fertilisation.

5

## BACKGROUND OF THIS INVENTION

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common  
10 general knowledge in the field.

Several meiosis activation substances (hereinafter designated MAS) have been found. When MAS are kept in a medium containing oocytes, the oocytes become more prone to become fertilised. However, a major problem with the use of MAS is that, usually, they  
15 have a very low solubility.

## SUMMARY OF THIS INVENTION

The present invention relates to a composition containing MAS or a derivative thereof  
20 which can be dissolved in an aqueous medium.

The invention further relates to a composition containing MAS or a derivative thereof which can be dissolved in an aqueous medium without any physical influence such as heating, stirring, or ultrasound treatment.  
25

According to a first aspect, the present invention provides an aqueous solution of a solid composition comprising a meiosis activating substance (MAS) and an additive which is a protein or a phosphoglyceride, wherein the solid composition has a content of protein or phosphoglyceride higher than 99% (weight/weight).  
30

According to a second aspect, the present invention provides an aqueous solution comprising a meiosis activating substance (MAS) and an additive which is a protein or a

phosphoglyceride, wherein the ratio of MAS to said protein or phosphoglyceride in said aqueous solution is at least 1:150 (weight/weight).

According to a third aspect, the present invention provides a solid composition  
5 comprising 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol and an additive which is a protein or a phosphoglyceride.

According to a fourth aspect, the present invention provides an aqueous solution comprising the composition of the third aspect.

10

According to a fifth aspect, the present invention provides a device comprising a hollow, the hollow comprising a composition of the third aspect.

According to a sixth aspect, the present invention provides a device comprising a  
15 hollow, the hollow comprising a solution of the fourth aspect.



According to a seventh aspect, the present invention provides a device comprising a hollow, the hollow comprising a solution of the first aspect.

20 Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

## 25 DETAILED DESCRIPTION OF THIS INVENTION

The solubility of a preferred MAS, i.e., FF-MAS, in water is very low, i.e., approximately 20 picogram/ml (corresponding to  $2 \times 10^{-5}$   $\mu$ g/ml), and in ethanol the solubility is substantially higher, i.e., approximately 4 mg/ml. According to our  
30 preliminary investigations, the highest solubility of FF-MAS in a mixture of ethanol and water (1:2.5) is approximately 0.4 mg/ml. Several other MAS have a similar low solubility in water.

Surprisingly, it has now been found that a solid composition containing MAS and an additive have good solubility in water. The additives are components which, when added to MAS, provide a composition which can be used to prepare an aqueous solution containing MAS.



Examples of additives are water soluble proteins such as serum albumin, e.g. human serum albumin (hereinafter designated HSA), optionally in recombinant form, enzymes and phosphoglycerider such as phosphatidylethanolamin, phosphatidylcholine, phosphatidylserine, phosphatidylinositol.

Preferably, the compositions of this invention have a content of water below 10 %, preferably below 5%, more preferred below 1% (weight/weight).

Preferably, the compositions of this invention have a content of organic solvent below 10 %, preferably below 5%, more preferred below 1% (weight/weight).

Preferably, the compositions of this invention have a content of MAS below 1%, preferably below 0.1%, more preferred below 0.05% (weight/weight).

Preferably, the compositions of this invention have a content of additive higher than 99%, more preferred higher than 99.9%.

Preferred compositions of this invention are such which can be treated with an aqueous medium containing no or only low concentrations of organic solvent result in a solution containing MAS. Preferably, these aqueous media contain less than 1%, preferably less than 0.5%, more preferred less than 0.1% of organic solvent (weight/weight).

Earlier, several attempts to prepare compositions fulfilling this requirement have failed.

Herein, the term MAS designates compounds which mediate the meiosis of oocytes. More specifically, MASs are compounds which in the test described in Example 1 below has a percentage germinal vesicle breakdown (hereinafter designated GVB) which is significantly higher than the control. Preferred MAS are such having a percentage GVB of at least 50%, preferably at least 80%. Examples of preferred MASs are 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol (hereinafter designated FF-MAS); 4,4-dimethyl-5 $\alpha$ -cholest-8,14,24-trien-3 $\beta$ -ol hemisuccinate; 5 $\alpha$ -cholest-8,14-dien-3 $\beta$ -ol; 5 $\alpha$ -cholest-8,14-dien-3 $\beta$ -ol hemisuccinate; (20S)-cholest-5-en-3 $\beta$ ,20-diol; 3 $\beta$ -hydroxy-4,4-dimethyl-5 $\alpha$ -chola-8,14-dien-24-oic acid-N-(methionine) amide; and cholest-5-en-16 $\beta$ -ol. Further examples of MASs are mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically in Claim 1 thereof.

One way of preparing the compositions of this invention is to mix a solution of MAS in an organic solvent such as ethanol with an aqueous solution of the additive and, thereafter to wait

until the solvent is evaporated. The evaporation can be accelerated by using continuous air-flow over the product, vacuum, or any other feasible methods to remove the solvent. The product marketed could be a delivery system having one or more depressions or hollows. Hereinafter, these depressions and hollows are mutually designated hollows. At least one of these hollows contain a composition according to this invention. A convenient way of placing the solid MAS therein is first to place a solution containing MAS and the additive in the hollow and thereafter to evaporate the solution. In this way, the evaporation residue, i.e., the composition according to this invention, is placed directly in the hollow in said device (delivery system).

10

Since the composition of this invention is to be used for the treatment of oocytes, it is important that the composition of this invention does not contain constituents which influence the oocytes negatively.

15 One way of using the compositions of this invention is to dissolve the composition in an aqueous medium such as water and then, if desired, to add other constituents which may have a favourable influence on the maturation of the oocytes.

Another way of using the composition is to dissolved it in a media normally used for in vitro maturation.

20

The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, in any combination thereof, be material for realising the invention in diverse forms thereof.

25

#### Example 1

30 Method used for determining whether a compound is a MAS or not.

Oocytes were obtained from immature female mice (C57BL/6J x DBA/2J F1, Bomholtgaard, Denmark) weighing 13-16 grams, that were kept under controlled temperature (20-22 °C), light (lights on 06.00-18.00) and relative humidity (50-70%). The mice received an intra-  
35 peritoneal injection of 0.2 ml gonadotropins (Gonal-F, Serono) containing 20 IU FSH and 48

hours later the animals were killed by cervical dislocation. The ovaries were dissected out and the oocytes were isolated in Hx-medium (see below) under a stereo microscope by manual rupture of the follicles using a pair of 27 gauge needles. Spherical oocytes displaying an intact germinal vesicle (hereinafter designated GV) were divided in cumulus enclosed oocytes (hereinafter designated CEO) and naked oocytes (hereinafter designated NO) and placed in  $\alpha$ -minimum essential medium ( $\alpha$ -MEM without ribonucleosides, Gibco BRL, Cat. No. 22561) supplemented with 3 mg/ml bovine serum albumin (BSA, Sigma Cat. No. A-7030), 5 mg/ml human serum albumin (HSA, State Serum Institute, Denmark), 0.23mM pyruvate (Sigma, Cat. No S-8636), 2 mM glutamine (Flow Cat. No. 16-801), 100 IU/ml penicillin and 100  $\mu$ g/ml streptomycin (Flow, Cat No. 16-700). This medium was supplemented with 3 mM hypoxanthine (Sigma Cat. No. H-9377) and designated Hx-medium.

The oocytes were rinsed three times in Hx-medium and oocytes of uniform size were divided into groups of CEO and NO. CEO and NO were cultured in 4-well multidishes (Nunclon, Denmark) in which each well contained 0.4 ml of Hx-medium and the compound to be tested in a concentration of 10  $\mu$ M. One control well (i.e., 35-45 oocytes cultured in identical medium with no addition of test compound) was always cultured simultaneously with 3 test wells (35-45 oocytes per well supplemented with test compound).

The oocytes were cultured in a humidified atmosphere of 5% CO<sub>2</sub> in air for 24 hours at 37°C. By the end of the culture period, the number of oocytes with GV, GVB and polar bodies (hereinafter designated PB), respectively, were counted using a stereo microscope (Wildt, Leica MZ 12). The percentage of GVB, defined as percentage of oocytes undergoing GVB per total number of oocytes in that well, was calculated as:

$$\% \text{ GVB} = ((\text{number of GVB} + \text{number of PB}) / \text{total number of oocytes}) \times 100.$$

25

## Example 2

Method used for determining whether a compound can be used as the additive in the compositions of this invention or not.

30

An additive for FF-MAS compositions are characterised by :

Improving the solubility of FF-MAS in ethanol/water (1:2.5 v/v)

Ensuring a clear solution of FF-MAS after reconstitution of the composition in MEM Alpha Medium.

5 Securing percent GVB is at least 50% preferable 80% when tested on oocytes obtained from immature female mice.

Prepare a saturated ethanolic solution of FF-MAS. Blend with an aqueous solution of the additive in the ration 1:2,5. By visual inspection control that surplus FF-MAS is available in the solution. Rotate the solution for 24 hours at room temperature. Filter the solution through  
10 0,22 $\mu$ m filter, determine the content of FF-MAS by HPLC and calculate the solubility. Transfer 350 $\mu$ l to 4-well dish and evaporate to dryness at room temperature. Add 500 $\mu$ l MEM ALPHA medium (Gibcocal). If a clear solution is obtained within half an hour, the composition is tested on oocytes obtained from immature female mice. % GVB obtained is at least 50%, preferable 80%, *vide* example 1.

15

### Example 3

Composition containing Human Serum Albumin (HSA).

20

In this example, 3 products were prepared. Referring to the table below, the stock solution of FF-MAS used for product 1, 2, and 3 contained 50, 500 and 3330  $\mu$ g/ml, respectively. For each of the products, the stock solution of HSA contained 20% HSA. The amount of said stock solutions used is stated in the table. For example, for product 1, 400  $\mu$ l of the FF-MAS  
25 stock solution was mixed with 1000  $\mu$ l of the HSA stock solution. After mixing of these stock solutions, the solutions were clear, and no precipitation was observed therein. After mixing, the amount thereof stated in the table was transferred to 4-well multi-dishes (Nuclon, Denmark). For example, for product i, 350  $\mu$ l of the mixture was transferred to the multi-dish Finally, the solutions were evaporated to dryness at room temperature. After evaporation,  
30 some of he products appears as an opalescent, clear film in the dishes, other are invisible to the human eye. The highest concentration of FF-MAS dissolved in this example is 0.95 mg/ml.

Before use, 500  $\mu$ l MEM ALPHA Medium (Gibcocal) is added, and a clear solution of FF-  
35 MAS and HSA is obtained within half an hour at room temperature.

	4-well-multi dish No. 1	4-well-multi dish No. 2	4-well-multi dish No. 3
FF-MAS solution in ethanol, 50 µg/ml	400 µl	-	-
FF-MAS solution in ethanol, 500 µg/ml	-	400 µl	-
FF-MAS solution in ethanol, 3.33 mg/ml	-	-	450 µl
HSA solution in water, 20%	1000 µl	1000 µl	1125 µl
Amount transferred to multi-dish	350 µl	350 µl	525 µl
Ratio between FF-MAS and HSA	1 : 10,000	1 : 1,000	1 : 150
Appearance of solutions before evaporation	clear, colourless solutions, without precipitation		

#### 5 Example 4

Compositions containing Human Serum Albumin (HSA).

Analogously as described in the previous example, solutions of FF-MAS in water/ethanol  
 10 containing HSA were prepared in the concentrations stated below by sample mixing at room  
 temperature. After preparation, the solutions were clear, and no precipitation was observed.  
 The solutions were transferred to 4-well multi-dishes (Nuclon, Denmark). Finally, the solu-  
 tions were evaporated to dryness at room temperature.

15 Before use, 500 µl MEM ALPHA Medium (Gibcocal) is added, and within half an hour at  
 room temperature, a clear solution of FF-MAS and HSA is obtained.

The formulations were tested on oocytes obtained from immature female mice. % GVB for  
 the respective formulation are stated in the table below.

	7		
	4-well-multi dish No. 1	4-well-multi dish No. 2	4-well-multi dish No. 3
FF-MAS solution in ethanol, 5.22 µg/ml	100 µl	-	-
FF-MAS solution in ethanol, 26.1 µg/ml	-	100 µl	-
FF-MAS solution in ethanol, 261 mg/ml	-	-	100 µl
HSA solution in water, 20%	250 µl	250 µl	250 µl
Ratio between FF-MAS and HSA	1 : 10,000	1 : 2,000	1 : 200
Theoretical quantity of FF-MAS per well	0.5 µg	2.5 µg	25 µg
% GVB	72	93	91

#### Example 5

5

Compositions containing Human Serum Albumin (HSA).

Analogously as described in the previous example, solutions of FF-MAS in water/ethanol containing HSA were prepared in the concentrations stated below by sample mixing at room temperature. After preparation, the solutions were clear, and no precipitation was observed. The solutions were transferred to 4-well multi-dishes (Nuclon, Denmark). Finally, the solutions were evaporated to dryness at room temperature.

Before use, 500 µl MEM ALPHA medium (Gibcocal) is added, and within half an hour at room temperature, a clear solution of FF-MAS and HSA is obtained.

The concentration of FF-MAS after reconstitution was determined by HPLC, and the results are stated below. The formulations were tested on oocytes obtained from immature female mice. %GVB for the respective formulations are stated below.

20

4-well-multi-dish

	No. 1	No. 2	No. 3	No. 4	No. 5
FF-MAS solution in ethanol, 26.1 µg/ml	100 µl	-	-	-	-
FF-MAS solution in ethanol 7.83 µg/ml	-	100 µl	-	-	-
FF-MAS solution in ethanol, 5.22 mg/ml	-	-	100 µl	-	-
FF-MAS solution in ethanol, 2.5 µg/ml	-	-	-	100 µl	-
FF-MAS solution in ethanol, 0.5 µg/ml	-	-	-	-	100 µl
HSA solution in water, 20%	250 µl	250 µl	250 µl	250 µl	250 µl
Ratio between FF-MAS and HSA	1 : 100,000	1 : 20,000	1 : 10,000	1 : 6667	1 : 2000
Theoretical quantity of FF-MAS per well	0.05 µg	0.25 µg	0.5 µg	0.75 µg	2.5 µg
Percentage GVB	13	52	78	82	90

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. An aqueous solution of a solid composition comprising a meiosis activating substance (MAS) and an additive which is a protein or a phosphoglyceride, wherein the solid composition has a content of protein and/or phosphoglyceride higher than 99%  
5 (weight/weight).
2. The aqueous solution of claim 1, wherein the content of MAS is at least 0.001  $\mu\text{g/ml}$ .
3. The aqueous solution of claim 2, wherein the content of MAS is not more than 0.1 g/ml.
- 10 4. The aqueous solution of any one of claims 1 to 3, comprising an organic solvent content of less than 0.1% (weight/weight).
5. An aqueous solution comprising a meiosis activating substance (MAS) and an additive which is a protein or a phosphoglyceride, wherein the ratio of MAS to said protein or phosphoglyceride in said aqueous solution is at least 1:150 (weight/weight).
- 15 6. The solution of claim 5, wherein said additive is a protein.
7. The solution of claim 6, wherein the protein is human serum albumin.
8. The solution of claim 7, wherein the human serum albumin is recombinant human serum albumin.
9. The solution of any one of claims 5 to 8, wherein the content of MAS is at least  
20 0.001  $\mu\text{g/ml}$ .
10. The solution of claim 9, wherein the content of MAS is not more than 0.1 g/ml.
11. The solution of any one of claims 5 to 10, wherein said solution comprises an organic solvent content of less than 0.1%.
12. A solid composition comprising 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol and  
25 an additive which is a protein or a phosphoglyceride.
13. The composition of claim 12, wherein said composition has a content of water of below 10% (weight/weight).
14. The composition of claim 12, wherein said composition has a content of water of below 5% (weight/weight).
- 30 15. The composition of claim 12, wherein said composition has a content of water of below 1% (weight/weight).
16. The composition of any one of claims 12 to 15, wherein said composition has a content of organic solvent of below 10% (weight/weight).

17. The composition of any one of claims 12 to 15, wherein said composition has a content of organic solvent of below 5% (weight/weight).
18. The composition of any one of claims 12 to 15, wherein said composition has a content of organic solvent of below 1% (weight/weight).
- 5 19. The composition of any one of claims 12 to 18, wherein said composition has a content of 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol of below 50% (weight/weight).
20. The composition of any one of claims 12 to 18, wherein said composition has a content of 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol of below 20% (weight/weight).
21. The composition of any one of claims 12 to 18, wherein said composition has a  
10 content of 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol of below 10% (weight/weight).
22. The composition of any one of claims 12 to 21, wherein said additive is a protein.
23. The composition of any one of claims 12 to 22, wherein said protein is human serum albumin.
24. An aqueous solution comprising the composition of any one of claims 12 to 23.
- 15 25. A device comprising a hollow, the hollow comprising a composition of any one of claims 12 to 23.
26. A device comprising a hollow, the hollow comprising a solution of claim 24.
27. A device comprising a hollow, the hollow comprising a solution of any one of claims 1 to 11.
- 20 28. A aqueous solution of a solid composition, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
29. A aqueous solution comprising a meiosis activating substance (MAS) and a additive, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
- 25 30. A solid composition comprising 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
31. A device comprising a hollow, the hollow comprising a solid composition, the solid composition comprising 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-triene-3 $\beta$ -ol,  
30 substantially as herein described with reference to any one or more of the examples but excluding comparative examples.

32. A device comprising a hollow, the hollow comprising a solution of claim 24, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.

33. A device comprising a hollow, the hollow comprising a solution of any one of  
5 claims 1 to 11, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.

DATED this 18<sup>th</sup> day of April 2005

Shelston IP

Attorneys for: NOVO NORDISK A/S

10

